Surmodics Shares Decline 10% on Investors' Lofty Expectations for SurVeil [MarketWatch]
Surmodics, Inc. (SRDX)
Last surmodics, inc. earnings: 4/29 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
surmodics.gcs-web.com/investor-overview
Company Research
Source: MarketWatch
The stock is up 11% over the last 12 months. Advertisement The surface modification technologies provider said it now expects fiscal 2024 revenue to range from $117 million and $121 million, representing a decrease between 9% and 12% compared to fiscal 2023. It also forecast an adjusted loss between 87 cents and $1.17 a share. Surmodics previously forecast fiscal 2024 revenue to range from $116 million to $121 million and an adjusted loss per share between 97 cents and $1.32. The stock's decline on Thursday could be due to investors' expectations surrounding SurVeil drug-coated balloon, Surmodics's treatment for peripheral artery disease, said Mike Matson, analyst at Needham. Surmodics said sales in the first quarter were driven primarily by fulfillment of the initial stocking order for the SurVeil DCB from Abbott Vascular, its exclusive distribution partner for the product. But management on an earnings call noted that its guidance for the second quarter could reflect lower
Show less
Read more
Impact Snapshot
Event Time:
SRDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRDX alerts
High impacting Surmodics, Inc. news events
Weekly update
A roundup of the hottest topics
SRDX
News
- Surmodics, Inc. (NASDAQ: SRDX) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $71.00 price target on the stock.MarketBeat
- Surmodics, Inc. (NASDAQ: SRDX) had its price target lowered by analysts at Needham & Company LLC from $47.00 to $43.00. They now have a "buy" rating on the stock.MarketBeat
- SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]Yahoo! Finance
- Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance [Yahoo! Finance]Yahoo! Finance
- Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial GuidanceBusiness Wire
SRDX
Earnings
- 5/1/24 - Beat
SRDX
Sec Filings
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- 2/13/24 - Form SC
- SRDX's page on the SEC website